Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Sep;15(3):319-28.
doi: 10.1007/s10911-010-9186-9. Epub 2010 Aug 14.

The mammary gland vasculature revisited

Affiliations
Free article
Review

The mammary gland vasculature revisited

Anne-Catherine Andres et al. J Mammary Gland Biol Neoplasia. 2010 Sep.
Free article

Abstract

Concomitant with the extensive growth and differentiation of the mammary epithelium during pregnancy and lactation, and epithelial involution after weaning, the vasculature of the mammary gland undergoes repeated cycles of expansion and regression. Vascular expansion is effected by sprouting angiogenesis, intussusception and conceivably also vasculogenesis. The capacity of the epithelial cells to stimulate vascular growth and differentiation is dependent on the constellation of systemic and local hormones and growth factors as well as the changing demands for oxygenation and nutrient supply. This results in the release of angiogenic factors which stimulate endothelial cell growth and regulate vascular architecture. In contrast to the angiogenic phase of the mammary gland cycle, little is known about the control of vascular regression although this would possibly offer new insights into therapeutic possibilities against breast cancer. In this review we summarize knowledge regarding the mechanisms regulating the vasculature of the mammary gland and delineate the importance of the vasculature in the attainment of organ function. In addition, we discuss the angiogenic mechanisms observed during mammary carcinogenesis and their consequences for breast cancer therapy.

PubMed Disclaimer

References

    1. Mol Endocrinol. 2005 Aug;19(8):2006-19 - PubMed
    1. FASEB J. 2007 Dec;21(14):3994-4004 - PubMed
    1. Microsc Res Tech. 2001 Jan 15;52(2):182-9 - PubMed
    1. Oncogene. 2010 Jun 24;29(25):3639-49 - PubMed
    1. J Clin Endocrinol Metab. 2003 Jun;88(6):2695-8 - PubMed

Publication types

MeSH terms

LinkOut - more resources